脂质纳米颗粒封装的Dnai1mRNA在初级纤毛功能失调的小鼠细胞模型中拯救了纤毛活动
Amanda J Smith1,2, Patrick R Sears1, Mirko Hennig3
1Marsico Lung Institute/Cystic Fibrosis Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Journal of cell science
|September 18, 2025
概括
研究人员开发了一种通过脂质纳米颗粒传递的新型mRNA疗法,以恢复小鼠原发性纤维功能障碍 (PCD) 模型中的纤维功能. 这种治疗成功地挽救了纤毛活动,为DNAI1突变的PCD患者提供了新的治疗方法的希望.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 呼吸系统医学 呼吸系统医学
背景情况:
- 初级状腺动力障碍 (PCD) 是一种罕见的遗传疾病,由于状腺功能失调而导致慢性肺病.
- 目前对PCD的治疗方法有限,缺乏对潜在的纤毛缺陷进行校正疗法.
研究的目的:
- 评估选择性器官向脂质纳米颗粒 (SORT-LNPs) 输送DNAI1 mRNA的疗效,以恢复PCD的小鼠模型中的状功能.
- 评估基于mRNA的疗法与LNP输送作为PCD治疗的潜力.
主要方法:
- 使用来自Dnai1淘汰赛小鼠模型的小鼠鼻上皮细胞 (mNPEC) 培养物.
- 用含有优化Dnai1mRNA的SORT-LNP处理的mNPECs.
- 量化了DNAI1蛋白水平,轴突体的结合,以及纤毛节拍的频率.
主要成果:
- 在淘汰赛mNPEC中,SORT-LNP-Dnai1 mRNA治疗剂量依赖地增加了DNAI1蛋白水平.
- 恢复了DNAI1的纳入状轴膜,挽救了状活动.
- 达到正常的纤毛脉动频率,持续超过3周.
结论:
- 通过SORT-LNPs提供的基于mRNA的疗法可以在PCD的临床前模型中有效地挽救状功能.
- 这种方法对临床开发充满希望,作为DNAI1突变引起的PCD患者的治疗方法.
相关概念视频
Mechanism of Ciliary Motion
4.9K
The ciliary structures were first seen in 1647 by Antonie Leeuwenhoek while observing the protozoans. In lower organisms, these appendages are responsible for cell movement, while in higher organisms, these appendages help in the movement of the extracellular fluids within the body cavities.
The cilia are made up of microtubules in a 9+2 arrangement, with nine microtubule doublet ring bundles, surrounding a pair of central singlet microtubule bundles. The doublet microtubule bundles are...
The cilia are made up of microtubules in a 9+2 arrangement, with nine microtubule doublet ring bundles, surrounding a pair of central singlet microtubule bundles. The doublet microtubule bundles are...
4.9K
RNA Interference
27.8K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.8K


